Tributary Capital Management LLC Has $12.44 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Tributary Capital Management LLC lessened its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 0.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 343,962 shares of the specialty pharmaceutical company’s stock after selling 357 shares during the quarter. Tributary Capital Management LLC owned approximately 0.62% of Supernus Pharmaceuticals worth $12,438,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Dimensional Fund Advisors LP grew its stake in shares of Supernus Pharmaceuticals by 12.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company’s stock worth $76,690,000 after acquiring an additional 309,966 shares in the last quarter. Stephens Investment Management Group LLC grew its position in Supernus Pharmaceuticals by 1.8% in the 3rd quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock worth $60,246,000 after purchasing an additional 33,710 shares in the last quarter. Pacer Advisors Inc. increased its stake in Supernus Pharmaceuticals by 29.9% in the 3rd quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after buying an additional 403,028 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after buying an additional 74,438 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its stake in shares of Supernus Pharmaceuticals by 1.1% in the 3rd quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock worth $23,163,000 after buying an additional 7,833 shares during the last quarter.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, Director Georges Gemayel sold 14,213 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.62, for a total value of $520,480.06. Following the completion of the transaction, the director now owns 13,315 shares in the company, valued at $487,595.30. This trade represents a 51.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jack A. Khattar sold 125,000 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.68, for a total value of $4,585,000.00. Following the transaction, the chief executive officer now directly owns 926,172 shares of the company’s stock, valued at $33,971,988.96. The trade was a 11.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 154,213 shares of company stock valued at $5,660,180 over the last three months. Company insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN opened at $38.55 on Friday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $39.37. The business has a 50-day moving average of $36.83 and a 200 day moving average of $34.07. The firm has a market cap of $2.13 billion, a P/E ratio of 36.03 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.25. The firm had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The company’s revenue was up 14.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.29) earnings per share. As a group, research analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on SUPN. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cantor Fitzgerald assumed coverage on shares of Supernus Pharmaceuticals in a report on Monday, January 6th. They issued an “overweight” rating and a $57.00 price target on the stock. Finally, Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.